|
Feb 22
|
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
|
|
Dec 1
|
Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now
|
|
Nov 17
|
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
|
|
Nov 17
|
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
|
|
Nov 15
|
MAIA Biotechnology Announces $4 Million Registered Direct Offering
|
|
Oct 3
|
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
|
|
Sep 28
|
MAIA Biotechnology Announces Share Repurchase Program
|
|
Aug 21
|
MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|